Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Book

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC


  • Author : Anthony Faber
  • Publisher : Academic Press
  • Release Date : 2021-03-15
  • Genre: Science
  • Pages : 250
  • ISBN 10 : 0128228334
  • Total Read : 63
  • File Size : 9,5 Mb

DOWNLOAD BOOK
Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Summary:

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Book

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC


  • Author : Anthony Faber
  • Publisher : Academic Press
  • Release Date : 2023-02-13
  • Genre: Science
  • Pages : 150
  • ISBN 10 : 9780128228340
  • Total Read : 69
  • File Size : 13,5 Mb

DOWNLOAD BOOK
Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Summary:

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Third Generation EGFR Inhibitors Book

Third Generation EGFR Inhibitors


  • Author : Harun M. Patel
  • Publisher : Elsevier
  • Release Date : 2019-03-15
  • Genre: Medical
  • Pages : 290
  • ISBN 10 : 0081026617
  • Total Read : 93
  • File Size : 16,8 Mb

DOWNLOAD BOOK
Third Generation EGFR Inhibitors Summary:

EGFR inhibitors are useful tools in cancer therapeutics, but resistance to the first generations have significantly increased, meaning a new generation of improved inhibitors are needed with better efficacy and lower toxicity. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. Mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are then explored before a discussion of potential future trends. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems is a guide for medicinal chemists, drug developer, and researchers investigating cancer therapeutics, supporting them in the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and looks at how they may be able to overcome the constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors and reviews both their design strategies and typical anticancer activity

Overcoming Drug Resistance in Gynecologic Cancers Book

Overcoming Drug Resistance in Gynecologic Cancers


  • Author : Anonim
  • Publisher : Academic Press
  • Release Date : 2021-08-11
  • Genre: Science
  • Pages : 388
  • ISBN 10 : 9780128243008
  • Total Read : 62
  • File Size : 6,8 Mb

DOWNLOAD BOOK
Overcoming Drug Resistance in Gynecologic Cancers Summary:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Epigenetic Regulation in Overcoming Chemoresistance Book

Epigenetic Regulation in Overcoming Chemoresistance


  • Author : Chunfu Wu
  • Publisher : Academic Press
  • Release Date : 2021-06-26
  • Genre: Science
  • Pages : 144
  • ISBN 10 : 9780128236857
  • Total Read : 61
  • File Size : 14,7 Mb

DOWNLOAD BOOK
Epigenetic Regulation in Overcoming Chemoresistance Summary:

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Current Applications for Overcoming Resistance to Targeted Therapies Book

Current Applications for Overcoming Resistance to Targeted Therapies


  • Author : Myron R. Szewczuk
  • Publisher : Springer
  • Release Date : 2019-07-15
  • Genre: Medical
  • Pages : 320
  • ISBN 10 : 9783030214777
  • Total Read : 72
  • File Size : 12,7 Mb

DOWNLOAD BOOK
Current Applications for Overcoming Resistance to Targeted Therapies Summary:

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies Book

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies


  • Author : Ramasamy Paulmurugan
  • Publisher : Academic Press
  • Release Date : 2021-06-25
  • Genre: Science
  • Pages : 828
  • ISBN 10 : 9780128215685
  • Total Read : 98
  • File Size : 18,7 Mb

DOWNLOAD BOOK
Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies Summary:

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy Book

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy


  • Author : Anonim
  • Publisher : Academic Press
  • Release Date : 2022-01-14
  • Genre: Science
  • Pages : 294
  • ISBN 10 : 9780323905565
  • Total Read : 94
  • File Size : 16,5 Mb

DOWNLOAD BOOK
Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy Summary:

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field